DFFA: A Potential Drug Target and Biomarker (G1676)

Target Name: DFFA

NCBI ID: G1676

DFFA

DFFA: A Potential Drug Target and Biomarker

DFFA is a protein that is expressed in various tissues and cells throughout the body. Its function is not well understood, but it has been shown to play a role in the development and progression of diseases, including cancer. Therefore, it is a potential drug target and biomarker for the development of new therapies.

The DFFA Protein

DFFA is a member of the superfamily of proteins that are known as the F-actinin family. This family of proteins is characterized by the presence of a single transmembrane domain and a cytoplasmic tail that is involved in protein-protein interactions. DFFA is a 21-kDa protein that is expressed in various tissues and cells, including muscle, liver, and cancer cells.

Function and Regulation

DFFA is involved in the regulation of many different cellular processes, including cell adhesion, migration, and the formation of tight junctions. It is also involved in the regulation of the cytoskeleton and in the maintenance of cell structure.

One of the most interesting functions of DFFA is its role in the regulation of cell division. DFFA has been shown to play a role in the regulation of mitosis, the process by which a cell divides. It has been shown to promote the formation of sister chromatids during mitosis and to regulate the movement of chromosomes during the process.

In addition to its role in cell division, DFFA is also involved in the regulation of cell survival. It has been shown to play a role in the regulation of apoptosis, the process by which a cell undergoes programmed cell death. DFFA has been shown to promote the formation of apoptotic cells and to regulate the clearance of apoptotic cells from the body.

Potential Drug Target

DFFA is a potential drug target because of its involvement in the regulation of cellular processes that are important for the development and progression of diseases. Its involvement in cell division, cell survival, and the regulation of apoptosis makes it an attractive target for small molecules that can modulate these processes.

One of the most promising small molecules that can modulate DFFA is a compound called WQ101, which is a phospholipase C inhibitor. WQ101 has been shown to inhibit the activity of DFFA and to inhibit the formation of sister chromatids during mitosis. This suggests that WQ101 may be an effective drug against cancer.

In addition to its potential use as a cancer drug, WQ101 may also be useful as a biomarker for the diagnosis of cancer. Its ability to inhibit the activity of DFFA and to regulate the formation of sister chromatids during mitosis make it an attractive tool for the detection and diagnosis of cancer.

Conclusion

DFFA is a protein that is involved in the regulation of many different cellular processes, including cell division, cell survival, and the regulation of apoptosis. Its involvement in these processes makes it a potential drug target and biomarker for the development of new therapies. The compound WQ101, which is a phospholipase C inhibitor, is one of the most promising small molecules that can modulate DFFA and may be an effective drug against cancer. Further research is needed to fully understand the function and regulation of DFFA and to develop new treatments based on its properties.

Protein Name: DNA Fragmentation Factor Subunit Alpha

Functions: Inhibitor of the caspase-activated DNase (DFF40)

The "DFFA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DFFA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets